{
    "organizations": [],
    "uuid": "fb1d548b2915a432ec0b20ea30964195d6fd82b9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vertex-initiates-phase-3-studies-o/brief-vertex-initiates-phase-3-studies-of-vx-445-tezacaftor-and-ivacaftor-idUSFWN1S31SB",
    "ord_in_thread": 0,
    "title": "Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS\n* VERTEX PHARMACEUTICALS - FIRST PHASE 3 STUDY WILL EVALUATE ABOUT 360 PEOPLE WITH CF WHO HAVE 1 COPY OF F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION\n* VERTEX PHARMACEUTICALS INC - SECOND PHASE 3 STUDY WILL EVALUATE APPROXIMATELY 100 PEOPLE WITH CF WHO HAVE TWO COPIES OF F508DEL MUTATION\n* VERTEX - ANNOUNCES RESULTS FOR VX-561 WHEN DOSED AS PART OF A TRIPLE COMBO REGIMEN IN PHASE 2 STUDIES OF PEOPLE WITH 1 F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION\n* VERTEX PHARMACEUTICALS INC - VX-561 WHEN DOESED AS PART OF THE TRIPLE COMBINATION REGIMENS WERE GENERALLY WELL TOLERATED Source text for Eikon:\n ",
    "published": "2018-04-27T04:40:00.000+03:00",
    "crawled": "2018-04-27T16:49:14.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "vertex",
        "pharmaceutical",
        "inc",
        "vertex",
        "initiate",
        "phase",
        "study",
        "tezacaftor",
        "ivacaftor",
        "triple",
        "combination",
        "regimen",
        "people",
        "cystic",
        "fibrosis",
        "vertex",
        "pharmaceutical",
        "first",
        "phase",
        "study",
        "evaluate",
        "people",
        "cf",
        "copy",
        "f508del",
        "mutation",
        "minimal",
        "function",
        "mutation",
        "vertex",
        "pharmaceutical",
        "inc",
        "second",
        "phase",
        "study",
        "evaluate",
        "approximately",
        "people",
        "cf",
        "two",
        "copy",
        "f508del",
        "mutation",
        "vertex",
        "announces",
        "result",
        "dosed",
        "part",
        "triple",
        "combo",
        "regimen",
        "phase",
        "study",
        "people",
        "f508del",
        "mutation",
        "minimal",
        "function",
        "mutation",
        "vertex",
        "pharmaceutical",
        "inc",
        "doesed",
        "part",
        "triple",
        "combination",
        "regimen",
        "generally",
        "well",
        "tolerated",
        "source",
        "text",
        "eikon"
    ]
}